Allan Jonathan 4

What Happened

• Allan Jonathan, General Counsel & Corporate Secretary of Stoke Therapeutics (STOK), received two equity awards on February 17, 2026: a grant of 53,000 option-based awards (derivative) and 35,000 restricted stock units (RSUs). Both awards show $0 cash paid on grant — these are compensatory awards, not market purchases or sales.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (appears timely under Section 16 reporting rules).
• Award amounts and cash: 53,000 (options) @ $0.00; 35,000 (RSUs) @ $0.00 — no immediate cash exchanged or proceeds.
• Vesting for the 53,000 option award: vests 1/48 of the total award on March 15, 2026, then monthly (1/48 each month) thereafter, subject to continued service (Footnote F1).
• RSU details (35,000): each RSU converts to one share on settlement (Footnote F2); RSUs vest 1/4 annually with first tranche vesting February 15, 2027, subject to continued service (Footnote F3).
• Shares owned after the transaction: not specified in the excerpt of the filing.
• Filing status: filed two days after the transaction date (no late filing indicated in the provided data).

Context

• These entries are awards/grants (transaction code A) — they represent future economic interest contingent on vesting and do not represent an immediate purchase or sale of shares. Options will require vesting (and potentially exercise) before becoming stock ownership; RSUs convert to shares upon settlement after vesting. Such awards are common for executive compensation and do not, by themselves, indicate an insider buying or selling stock.